The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Open accessAbstract
The first cancer-targeted microRNA (miRNA) drug — MRX34, a liposome-based miR-34 mimic — entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L., & Weinberg, R. A. (2009) · Cell · doi:10.1016/j.cell.2009.03.047 · Cited by 820
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990
Natural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Self-citationA ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
Cited by
Long Noncoding RNAs in Cancer Pathways
Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 2,992
Long Noncoding RNA and Cancer: A New Paradigm
Bhan, A., Soleimani, M., & Mandal, S. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2634 · Cited by 2,861
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702
Jia, Q.-W., Chen, Z.-H., Ding, X.-Q., Liu, J.-Y., Ge, P.-C., An, F.-H., Li, L.-H., Wang, L.-S., Ma, W.-Z., Yang, Z.-J., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478071 · Cited by 1,691
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Self-citationceRNA in cancer: possible functions and clinical implications
Qi, X., Zhang, D.-H., Wu, N., Xiao, J.-H., Wang, X., & Ma, W. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103334 · Cited by 1,271
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
MicroRNAs as regulatory elements in immune system logic
Mehta, A., & Baltimore, D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.40 · Cited by 704
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0893 · Cited by 689
Self-citationMicroRNA Regulation of Atherosclerosis
Feinberg, M. W., & Moore, K. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306300 · Cited by 627
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Brozovich, F. V., Nicholson, C. J., Degen, C. V., Gao, Y. Z., Aggarwal, M., & Morgan, K. G. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.010652 · Cited by 542
Fromm, B., Billipp, T., Peck, L. E., Johansen, M., Tarver, J. E., King, B. L., Newcomb, J. M., Sempere, L. F., Flatmark, K., Hovig, E., et al. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092023 · Cited by 537
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
Self-citationlncRNAs and microRNAs with a role in cancer development
Liz, J., & Esteller, M. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.06.015 · Cited by 512
Jin, D., Guo, J., Wu, Y., Du, J., Yang, L., Wang, X., Di, W., Hu, B., An, J., Kong, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0830-6 · Cited by 501
RetractedMir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Long Noncoding RNAs in Patients With Acute Myocardial Infarction
Vausort, M., Wagner, D. R., & Devaux, Y. (2014) · Circulation Research · doi:10.1161/circresaha.115.303836 · Cited by 491
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Wu, Y.-L., Lin, Z.-J., Li, C.-C., Lin, X., Shan, S.-K., Guo, B., Zheng, M.-H., Li, F., Yuan, L.-Q., & Li, Z.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01333-7 · Cited by 476
MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance
Iqbal, M. A., Arora, S., Prakasam, G., Calin, G. A., & Syed, M. A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.003 · Cited by 449
Self-citationlncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals
Xing, Z., Lin, A., Li, C., Liang, K., Wang, S., Liu, Y., Park, P. K., Qin, L., Wei, Y., Hawke, D. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.013 · Cited by 447
Tools for Sequence-Based miRNA Target Prediction: What to Choose?
Riffo-Campos, Á., Riquelme, I., & Brebi-Mieville, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121987 · Cited by 432
Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment
Sun, Z., Yang, S., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., Xu, J., Xia, K., Chang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0831-z · Cited by 427
MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies
Kim, T., & Croce, C. M. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01050-9 · Cited by 407
McLean, M. H., & El-Omar, E. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.143 · Cited by 395
From Discovery to Function: The Expanding Roles of Long NonCoding RNAs in Physiology and Disease
Sun, M., & Kraus, W. L. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1034 · Cited by 395
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Cell-to-cell communication: microRNAs as hormones.
Bayraktar, R., Van Roosbroeck, K., & Calin, G. A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12144 · Cited by 361
Self-citationTargeting EMT in cancer: opportunities for pharmacological intervention
Davis, F. M., Stewart, T. A., Thompson, E. W., & Monteith, G. R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.006 · Cited by 361
Jin, D., Guo, J., Wu, Y., Yang, L., Wang, X., Du, J., Dai, J., Chen, W., Gong, K., Miao, S., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01161-1 · Cited by 344
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Basic biology and therapeutic implications of lncRNA
Khorkova, O., Hsiao, J., & Wahlestedt, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.012 · Cited by 341
Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review
Navickas, R., Gal, D., Laucevičius, A., Taparauskaitė, A., Zdanytė, M., & Holvoet, P. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw174 · Cited by 332
Junk DNA and the long non-coding RNA twist in cancer genetics
Ling, H., Vincent, K., Pichler, M., Fodde, R., Berindan-Neagoe, I., Slack, F. J., & Calin, G. A. (2015) · Oncogene · doi:10.1038/onc.2014.456 · Cited by 328
Self-citationNon-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Pietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303
Exosomes as divine messengers: are they the Hermes of modern molecular oncology?
Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., & Calin, G. A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.130 · Cited by 297
Self-citationBaumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Genomics in acute lymphoblastic leukaemia: insights and treatment implications
Roberts, K. G., & Mullighan, C. G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.38 · Cited by 287
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis
Dhamija, S., & Diederichs, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30039 · Cited by 272
Oligonucleotide Therapies: The Past and the Present
Lundin, K. E., Gissberg, O., & Smith, C. I. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.070 · Cited by 267
Kalla, R., Ventham, N. T., Kennedy, N. A., Quintana, J. F., Nimmo, E. R., Buck, A. H., & Satsangi, J. (2015) · Gut · doi:10.1136/gutjnl-2014-307891 · Cited by 267
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
Rao, M. S., Van Vleet, T. R., Ciurlionis, R., Buck, W. R., Mittelstadt, S. W., Blomme, E. A. G., & Liguori, M. J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00636 · Cited by 262
MicroRNAs as Therapeutic Targets and Biomarkers of Cardiovascular Disease
Olson, E. N. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009008 · Cited by 255
Hypoxia-inducible factor 1 and breast cancer metastasis
Liu, Z.-J., Semenza, G. L., & Zhang, H.-F. (2015) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b1400221 · Cited by 252
Lee, Y.-S., Kim, S. Y., Ko, E., Lee, J.-H., Yi, H.-S., Yoo, Y. J., Je, J., Suh, S. J., Jung, Y. K., Kim, J. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03389-2 · Cited by 233
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
Sakha, S., Muramatsu, T., Ueda, K., & Inazawa, J. (2016) · Scientific Reports · doi:10.1038/srep38750 · Cited by 201
Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
Chen, J., Liu, Q., He, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958790 · Cited by 164
Chen, J., & Chopp, M. (2018) · Stroke · doi:10.1161/strokeaha.117.018292 · Cited by 152
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Costa, A., Naranjo, J. D., Londono, R., & Badylak, S. F. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025676 · Cited by 135
Loher, P., Londin, E. R., & Rigoutsos, I. (2014) · Oncotarget · doi:10.18632/oncotarget.2405 · Cited by 133
β-Cell MicroRNAs: Small but Powerful
Filios, S. R., & Shalev, A. (2015) · Diabetes · doi:10.2337/db15-0831 · Cited by 106
Parsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.33 · Cited by 83
Viral Myocarditis—From Pathophysiology to Treatment
Schultheiss, H.-P., Baumeier, C., Aleshcheva, G., Bock, C.-T., & Escher, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225240 · Cited by 75
Liu, X., Yang, J., Zhang, Y., Fang, Y., Wang, F., Wang, J., Zheng, X., & Yang, J. (2016) · Scientific Reports · doi:10.1038/srep22811 · Cited by 63
MicroRNAs and miRceptors: a new mechanism of action for intercellular communication
Fabbri, M. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0486 · Cited by 65
Self-citationThinking small: towards microRNA-based therapeutics for anxiety disorders
Scott, K. A., Hoban, A. E., Clarke, G., Moloney, G. M., Dinan, T. G., & Cryan, J. F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.997873 · Cited by 52
MicroRNAs and ceRNAs: therapeutic implications of RNA networks
Giza, D. E., Vasilescu, C., & Calin, G. A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920812 · Cited by 51
Self-citationProtective effect of microRNA-138 against cerebral ischemia/reperfusion injury in rats
TANG, X.-J., YANG, M.-H., CAO, G., LU, J.-T., LUO, J., DAI, L.-J., HUANG, K.-M., & ZHANG, L. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3021 · Cited by 31
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Ling, H., Fabbri, M., & Calin, G. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-10-31
- Volume
- 12
- Issue
- 11
- Pages
- 847-865
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2163169932
- Cited by
- 1,465
- References
- 175
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.